This publication has been discontinued on September 9, 2011.
Abstract
Renal Cancer - Drug Pipeline Analysis and Market Forecasts to 2016
Summary
GlobalData, the industry analysis specialist’s new report on the
pharmaceutical and healthcare industry, “Renal Cancer - Drug
Pipeline Analysis and Market Forecasts to 2016” is an essential source
of information and analysis on the global renal cancer market. The report
identifies the key trends shaping and driving the global renal cancer market,
a key segment within the pharma industry. The report also provides insight on
the prevalent competitive landscape and the emerging players expected to bring
significant shift in the market positioning of the existing market leaders.
Most importantly, the report provides valuable insight on the pipeline
products within the global renal cancer sector.
This report is built using data and information sourced from proprietary
databases, primary and secondary research and in house analysis by
GlobalData’s team of industry experts.
Scope
The scope of the report includes:
- Annualized global renal cancer
disease market revenues data from 2001 to 2009, forecast forward for seven
years to 2016.
- Geographic markets covered in this report include the
US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis
data providing a split across different phases, mechanism of action being
developed and emerging trends. The key classes of mechanism of action include
targeted therapies, EGFR, RAF inhibitors and LAK and NK cells enhancers.
- Analysis of the current and future market competition in the global renal
cancer market. The key market players covered are F. Hoffmann-La Roche Ltd,
Pfizer Inc., Novartis AG, Amgen Inc., and WILEX AG.
- Insightful review
of the key industry drivers, restraints and challenges. Each trend is
independently researched to provide qualitative analysis of its
implications.
- Key topics covered include a strategic competitor
assessment, market characterization, unmet needs and implications for future
market associated with renal cancer.
Reasons to buy
The report will enhance your decision making capability in a more rapid and
time sensitive manner. It will allow you to:
- Develop and design your
in-licensing and out-licensing strategies through review of pipeline products
and technologies and by identifying companies with the most robust
pipeline.
- Develop business strategies by understanding the trends
shaping and driving the global renal cancer market.
- Drive revenues by
understanding key trends, innovative products and technologies, market
segments and companies likely to impact the global renal cancer market in
future.
- Formulate effective sales and marketing strategies by
understanding the competitive landscape and by analyzing the performance of
various competitors.
- Identify emerging players with potentially strong
product portfolio and create effective counter-strategies to gain
competitive advantage.
- Organize your sales and marketing efforts by
identifying the market categories and segments that present maximum
opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global renal cancer market landscape?
- Identify, understand and capitalize.
Table of Contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2
Renal Cancer: Market Characterization 6
2.1 Renal Cancer Market Size 6
2.2 Renal Cancer Market Forecast and CAGR 6
2.3 Drivers and Barriers for
Renal Cancer Market 7
2.3.1 Drivers for Renal Cancer Market 7
2.3.2
Barriers for Renal Cancer Market 8
2.4 Opportunity and Unmet Need 8
2.5 Key Takeaway 9
3 Renal Cancer Market: Competitive Assessment 10
3.1 Overview 10
3.2 Strategic Competitor Assessment 10
3.3 Product
Profile for the Major Marketed Products in Renal Cancer Market 11
3.3.1
Avastin (bevacizumab) 11
3.3.2 Sutent (sunitinib malate) 12
3.3.3
Votrient (pazopanib) 13
3.3.4 Afinitor (everolimus) 14
3.3.5 Nexavar
(sorafenib) 14
3.3.6 Torisel (temsirolimus) 15
3.4 Major Marketed
Products Comparison in Renal Cancer Market 16
3.5 Key Takeaway 17
4
Renal Cancer Market: Pipeline Assessment 18
4.1 Overview 18
4.2
Strategic Pipeline Assessment 18
4.2.1 Technology Trends Analytic
Framework 18
4.3 Renal Cancer Therapeutics - Promising Drugs Under
Clinical Development 20
4.4 Molecule Profile for Promising Drugs under
Clinical Development 20
4.4.1 Oncophage (vitespen) 20
4.4.2 Axitinib
21
4.4.3 TroVax 21
4.4.4 ANYARA 22
4.4.5 RENCAREX 22
4.5 Renal
Cancer Therapeutics Market - Clinical Pipeline by Therapeutic Class
23
4.6 Renal Cancer Pipeline - Pipeline by Clinical Phases of
Development 24
4.6.1 Renal Cancer Therapeutics - Regulatory Filed
Clinical Pipeline 24
4.6.2 Renal Cancer Therapeutics - Phase III
Clinical Pipeline 25
4.6.3 Renal Cancer Therapeutics - Phase II
Clinical Pipeline 28
4.6.4 Renal Cancer Therapeutics - Phase I
Clinical Pipeline 44
4.6.5 Renal Cancer Therapeutics - Preclinical
Pipeline 48
4.6.6 Renal Cancer Therapeutics - Drug Discovery
Pipeline 49
4.7 Key Takeaway 49
5 Global Renal Cancer: Implications
for Future Market Competition 50
6 Global Renal Cancer Market: Future
Players in the Renal Cancer Market 51
6.1 Introduction 51
6.2 F.
Hoffmann-La Roche Ltd/Genentech, Inc. 51
6.2.1 Company Overview 51
6.2.2 Business Description 52
6.3 Pfizer Inc. 54
6.3.1 Company
Overview 54
6.3.2 Business Description 55
6.4 Novartis AG 58
6.4.1
Company Overview 58
6.4.2 Business Description 58
6.5 Amgen Inc.
60
6.5.1 Company Overview 60
6.5.2 Business Description 60
6.6
WILEX AG 62
6.6.1 Company Overview 62
6.6.2 Business Description
62
7 Global Renal Cancer Market: Appendix 64
7.1 Definitions 64
7.2 Acronyms 64
7.3 Research Methodology 65
7.3.1 Coverage 65
7.3.2 Secondary Research 65
7.3.3 Forecasting 66
7.3.4 Primary
Research 68
7.3.5 Expert Panels 69
7.4 Contact Us 69
7.5
Disclaimer 69
7.6 Sources 70
1.1 List of Tables
Table 1:
Global Renal Cancer Therapeutics Market, Revenue Forecasts ($ m),
2001-2009 7
Table 2: Global Renal Cancer Therapeutics Market,
Revenue Forecasts ($ m), 2010-2016 7
Table 3: Major marketed
products comparison in Renal Cancer Market, 2009 16
Table 4: Renal Cancer
Therapeutics - Most Promising Drugs Under Clinical Development, 2009
20
Table 5: Renal Cancer Therapeutics - Regulatory Filed Clinical
Pipeline, 2009 24
Table 6: Renal Cancer Therapeutics - Phase III
Clinical Pipeline, 2009 25
Table 7: Renal Cancer Therapeutics -
Phase II Clinical Pipeline, 2009 28
Table 8: Renal Cancer Therapeutics
- Phase I Clinical Pipeline, 2009 44
Table 9: Renal Cancer
Therapeutics - Preclinical Pipeline, 2009 48
Table 10: Renal Cancer
Therapeutics - Drug Discovery Pipeline, 2009 49
Table 11: F.
Hoffmann-La Roche Ltd/Genentech, Inc. - Oncology Pipeline Products,
2009 53
Table 12: F. Hoffmann-La Roche Ltd/Genentech, Inc. - Renal
Cancer Pipeline Products, 2009 54
Table 13: Pfizer Inc - Oncology
Pipeline Products, 2009 56
Table 14: Pfizer Inc - Renal Cancer
Pipeline Products, 2009 57
Table 15: Novartis AG - Oncology
Pipeline Products, 2009 59
Table 16: Novartis AG - Renal Cancer
Pipeline Products, 2009 60
Table 17: Amgen Inc. - Oncology Pipeline
Products, 2009 61
Table 18: Amgen Inc. - Renal Cancer Pipeline
Products, 2009 62
Table 19: WILEX AG - Oncology Pipeline Products,
2009 63
Table 20: WILEX AG - Renal Cancer Pipeline Products, 2009
63
1.2 List of Figures
Figure 1: Global Renal Cancer
Therapeutics Market Forecast, 2001-2016 6
Figure 2: Renal Cancer
Therapeutics Market - Opportunity and Unmet Need, 2009 8
Figure 3:
Renal Cancer Therapeutics Market - Strategic Competitor Assessment, 2009
10
Figure 4: Technology Trends Analytic Framework of the Renal Cancer
Pipeline, 2009 18
Figure 5: Technology Trends Analytic Framework of the
Renal Cancer Pipeline - Description, 2009 19
Figure 6: Renal Cancer
Therapeutics Market - Clinical Pipeline by Mechanism Of Action, 2009
23
Figure 7: Renal Cancer Pipeline by Phase of Clinical Development, 2009
24
Figure 8: Renal Cancer Therapeutics Market - Strategic
Competitor Assessment, 2009 50
Figure 9: Renal Cancer Therapeutics Market
- Clinical Pipeline by Company, 2009 51
Figure 10: GlobalData
Methodology 65
Figure 11: GlobalData Market Forecasting Model 68
